About Publications

Publications from the National Academies of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes Health and Medicine Division (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.


  • Ethical Review and Oversight Issues in Research Involving ... Released: January 05, 2015
    On December 2–3, 2014, the Institute of Medicine’s (IOM’s) Board on Health Sciences Policy held a workshop to facilitate dialogue among stakeholders about the ethical issues surrounding study design and informed consent for regulated research studies involving standard of care interventions.
  • Advancing Therapeutic Development for Dry Age-Related ... Released: January 02, 2015
    Age-related macular degeneration (AMD) is the leading cause of blindness among white Americans and others of European descent, with lower prevalence among those of Asian, Latino, or African ancestry. The overall prevalence of AMD is approximately 8.7 percent worldwide and is expected to rise to 196 million people worldwide by 2020 and 288 million by 2040 (Wong et al., 2014). AMD typically affects people age 50 and older, and the prevalence increases with age, particularly after the age of 75.
  • Enabling Rapid and Sustainable Public Health Research ... Released: November 14, 2014
    The Forum on Medical and Public Health Preparedness for Catastrophic Events, in collaboration with the National Institutes of Health, the Office of the Assistant Secretary for Preparedness and Response, and the Centers for Disease Control and Prevention, hosted a public workshop that examined strategies and diversified partnerships to enable methodologically and ethically sound public health and medical research during future emergencies. Discussions supporting this new infrastructure included considerations of rapid funding mechanisms, data collection methods, rapid institutional review board approval processes, and integration of research into an operational response.
  • Research Priorities to Inform Public Health and Medical ... Released: November 14, 2014
    The current epidemic of Ebola Virus Disease (EVD), cause by a filovirus, has spread internationally, now affecting multiple continents, and has become the worst EVD outbreak in history since its discovery in 1976. While the Ebola viruses have typically been studied in laboratory settings, additional biomedical and public health research in real world settings can best prepare the United States to safeguard the public and at-risk workers.
  • Regional Disaster Response Coordination to Support Health ... Released: November 03, 2014
    When a disaster strikes, it rarely impacts just one jurisdiction. It is important for jurisdictions to consider how they will respond to a scenario in which the entire region is impacted. To explore these considerations, the Institute of Medicine's Forum on Medical and Public Health Preparedness for Catastrophic Events organized a workshop in 2014 to examine how information and incident management can augment response efforts in a complex, regional emergency. This brief summary highlights the presentation and discussion of the workshop.
  • Characterizing and Communicating Uncertainty in the ... Released: September 26, 2014
    On February 12 and May 12, 2014, the Institute of Medicine’s (IOM’s) Forum on Drug Discovery, Development, and Translation held public workshops at FDA Headquarters in White Oak, MD, to advance the development of more systematic and structured approaches to characterize and communicate the sources of uncertainty in the assessment of benefits and risks, and to consider their implications for pharmaceutical regulatory decisions. This report is a summary of the February 12 and May 12, 2014 workshops.
  • Promising the Best Practices in Total Worker Health (TM) ... Released: September 22, 2014
    In May 2014, with support from NIOSH, the Institute of Medicine (IOM) organized a 1-day workshop on Total Worker Health. Rather than a review of published literature, this workshop sought input from a wide variety of on-the-ground stakeholders regarding their experiences with integrating occupational safety and health protection with health promotion in the workplace.
  • Assessing Genomic Sequencing Information for Health Care ... Released: July 22, 2014
    Clinical use of DNA sequencing relies on identifying linkages between diseases and genetic variants or groups of variants. More than 140,000 germline mutations have been submitted to the Human Gene Mutation Database and almost 12,000 single nucleotide polymorphisms have currently been associated with various diseases, including Alzheimer’s and type 2 diabetes, but the majority of associations have not been rigorously confirmed and may play only a minor role in disease. Because of the lack of evidence available for assessing variants, evaluation bodies have made few recommendations for the use of genetic tests in health care.
  • Assessing Genomic Sequencing Information for Health Care ... Released: July 22, 2014
    Clinical use of DNA sequencing relies on identifying linkages between diseases and genetic variants or groups of variants. More than 140,000 germline mutations have been submitted to the Human Gene Mutation Database and almost 12,000 single nucleotide polymorphisms have currently been associated with various diseases, including Alzheimer’s and type 2 diabetes, but the majority of associations have not been rigorously confirmed and may play only a minor role in disease. Because of the lack of evidence available for assessing variants, evaluation bodies have made few recommendations for the use of genetic tests in health care.
  • Improving Access to Essential Medicines for Mental ... Released: July 14, 2014
    Recognizing the limitations of most SSA countries to effectively treat MNS disorders, the Forum on Neuroscience and Nervous System Disorders of the Institute of Medicine convened a workshop in Addis Ababa, Ethiopia, in January 2014. The workshop brought together key stakeholders to discuss opportunities for achieving long-term affordable access to medicines for MNS disorders and to consider frameworks and strategies that have been successful in other countries and for different diseases. In particular, the workshop was organized around a series of focused discussions on four challenge areas: insufficient demand, inappropriate selection, ineffective supply chains, and high pricing and poor financing. This document summarizes the workshop.